ZNF630

Summary

ZNF630 (zinc finger protein 630, HGNC:28855) is a protein-coding gene on chromosome Xp11.23, encoding Zinc finger protein 630 (Q2M218). May be involved in transcriptional regulation.

This gene encodes a protein containing an N-terminal Kruppel-associated box-containing (KRAB) domain and 13 Kruppel-type C2H2 zinc finger domains. This gene resides on an area of chromosome X that has been implicated in nonsyndromic X-linked cognitive disability. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 57232 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 79 total
• MANE Select transcript: NM_001282201

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28855
Approved symbol	ZNF630
Name	zinc finger protein 630
Location	Xp11.23
Locus type	gene with protein product
Status	Approved
Aliases	BC037316, dJ54B20.2, FLJ20573, MGC138344
Ensembl gene	ENSG00000221994
Ensembl biotype	protein_coding
OMIM	300819
Entrez	57232

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 nonsense_mediated_decay

ENST00000276054, ENST00000409324, ENST00000421903, ENST00000428463, ENST00000428686, ENST00000442455, ENST00000616492, ENST00000627643, ENST00000871921, ENST00000951017, ENST00000951018

RefSeq mRNA: 4 — MANE Select: NM_001282201 NM_001037735, NM_001190255, NM_001282201, NM_001282202

CCDS: CCDS35237

Canonical transcript exons

ENST00000276054 — 5 exons

Exon	Start	End
ENSE00003663158	48060819	48060945
ENSE00003680768	48060450	48060545
ENSE00003896539	48066872	48067061
ENSE00003896801	48071267	48071640
ENSE00003896933	48057516	48060203

Expression profiles

Bgee: expression breadth ubiquitous, 179 present calls, max score 78.93.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4793 / max 26.2194, expressed in 832 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199149	1.4793	832

Top tissues by expression

239 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	78.93	gold quality
left ventricle myocardium	UBERON:0006566	78.90	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.79	silver quality
upper arm skin	UBERON:0004263	74.19	gold quality
islet of Langerhans	UBERON:0000006	73.82	gold quality
cortical plate	UBERON:0005343	73.74	gold quality
kidney epithelium	UBERON:0004819	73.66	gold quality
left ovary	UBERON:0002119	73.49	gold quality
thoracic aorta	UBERON:0001515	72.72	gold quality
lower esophagus mucosa	UBERON:0035834	72.72	gold quality
ascending aorta	UBERON:0001496	72.69	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.59	gold quality
descending thoracic aorta	UBERON:0002345	72.58	gold quality
endocervix	UBERON:0000458	72.53	gold quality
colonic epithelium	UBERON:0000397	72.29	gold quality
right ovary	UBERON:0002118	72.10	gold quality
smooth muscle tissue	UBERON:0001135	72.09	gold quality
aorta	UBERON:0000947	72.00	gold quality
right coronary artery	UBERON:0001625	71.77	gold quality
cerebellar hemisphere	UBERON:0002245	71.57	gold quality
popliteal artery	UBERON:0002250	71.57	gold quality
cerebellar cortex	UBERON:0002129	71.55	gold quality
tibial artery	UBERON:0007610	71.55	gold quality
cardiac atrium	UBERON:0002081	71.35	gold quality
ganglionic eminence	UBERON:0004023	71.23	gold quality
right lobe of thyroid gland	UBERON:0001119	71.22	gold quality
right atrium auricular region	UBERON:0006631	71.09	gold quality
left coronary artery	UBERON:0001626	71.04	gold quality
thyroid gland	UBERON:0002046	70.97	gold quality
ectocervix	UBERON:0012249	70.95	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-CURD-10	no	228.45
E-ANND-3	no	5.33

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

23 targeting ZNF630, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-488-5P	99.28	68.12	821
HSA-MIR-4721	99.26	66.05	818
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-6731-3P	98.61	67.86	749
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-4778-5P	97.96	68.06	1634
HSA-MIR-204-3P	97.80	66.84	1656
HSA-MIR-4646-5P	97.70	66.84	1692
HSA-MIR-3928-3P	97.61	66.53	1096
HSA-MIR-4314	97.50	67.30	1369
HSA-MIR-96-3P	97.47	68.03	839

Literature-anchored findings (GeneRIF, showing 1)

• Detected 12 ZNF630 deletions in a total of 1,562 male patients with mental retardation from Brazil, USA, Australia, and Europe. The breakpoints were analyzed in 10 families, and in all cases they were located within two segmental duplications. (PMID:20186789)

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 630 — Q2M218 (reviewed: Q2M218)

All UniProt accessions (7): Q2M218, A0A087WXA8, A0A0D9SER6, A0A6E1WMD9, B2ZWG8, B2ZWG9, F8WCH7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q2M218-1	1	yes
Q2M218-2	2

RefSeq proteins (4): NP_001032824, NP_001177184, NP_001269130, NP_001269131 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (18 total): zinc finger region 14, chain 1, domain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2M218-F1	67.64	0.13

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 22 (showing top): CAMPS_COLON_CANCER_COPY_NUMBER_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, chrXp11, ZWANG_DOWN_BY_2ND_EGF_PULSE, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, MIR4422, MIR4524A_3P, MIR139_5P, MIR3928_3P, MIR26A_1_3P, MIR26A_2_3P, GSE14000_UNSTIM_VS_4H_LPS_DC_UP, GSE14000_4H_VS_16H_LPS_DC_DN, OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_DN, GOMF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nuclear lumen (GO:0031981)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nucleus	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

272 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF630	SPACA5B	Q96QH8	627
ZNF630	ITIH6	Q6UXX5	447
ZNF630	CFAP47	Q6ZTR5	447
ZNF630	EOLA1	Q8TE69	447
ZNF630	OR6C6	A6NF89	433
ZNF630	CCDC59	Q9P031	418
ZNF630	INTS6L	Q5JSJ4	401
ZNF630	TMEM185A	Q8NFB2	379
ZNF630	OR6C65	A6NJZ3	370
ZNF630	SSX3	Q99909	352
ZNF630	CCDC85B	Q15834	311
ZNF630	ASB9	Q96DX5	310
ZNF630	POGZ	Q7Z3K3	306
ZNF630	TSEN54	Q7Z6J9	306
ZNF630	MAGEA9B	P43362	302

IntAct

2 interactions, top by confidence:

A	B	Type	Score
GPC3	PXDNL	psi-mi:“MI:0914”(association)	0.350

ESM2 similar proteins: A0A1W2PQL4, A0JPL0, A2RRD8, A6NHJ4, A6NP11, B4DX44, O75346, O95780, P0CB33, P21506, P51508, P52738, Q0D2J5, Q0VGE8, Q12901, Q13360, Q14593, Q15973, Q2M218, Q2M3X9, Q2VY69, Q3SXZ3, Q5HY98, Q5RCJ2, Q5VIY5, Q6J6I6, Q7L2R6, Q86XU0, Q86Y25, Q8IW36, Q8IYN0, Q8IYX0, Q8N782, Q8N883, Q8N9Z0, Q8NDP4, Q95K49, Q969W8, Q96H40, Q96N58

Diamond homologs: A0JPK3, A8MT65, C9JN71, E9QAG8, G3X9G7, O75820, P16373, P16374, P16415, P17017, P17024, P17025, P51815, P52737, Q08AG5, Q08ER8, Q0D2J5, Q15973, Q2M218, Q3KP31, Q3V080, Q494X3, Q4R4C7, Q5MYW4, Q5R9F0, Q5R9S5, Q5REI6, Q5REK1, Q68EA5, Q6P560, Q6P5C7, Q6ZQV5, Q7L945, Q86T29, Q8BGV5, Q8C6P8, Q8IYI8, Q8IZC7, Q8N7K0, Q8N972

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1573 predictions. Top by Δscore:

Variant	Effect	Δscore
X:48008532:ATGG:A	donor_loss	1.0000
X:48008534:GGT:G	donor_loss	1.0000
X:48008535:G:C	donor_loss	1.0000
X:48008536:T:A	donor_loss	1.0000
X:48071341:C:A	donor_gain	1.0000
X:48071345:T:TA	donor_gain	1.0000
X:48071353:T:TA	donor_gain	1.0000
X:48071354:C:A	donor_gain	1.0000
X:47983408:GCCCC:G	acceptor_loss	0.9900
X:47983411:CCTG:C	acceptor_loss	0.9900
X:47983412:C:A	acceptor_loss	0.9900
X:47983413:T:A	acceptor_loss	0.9900
X:47988520:ATACC:A	donor_loss	0.9900
X:47988521:TACCT:T	donor_loss	0.9900
X:47988522:ACCTG:A	donor_loss	0.9900
X:47988523:C:CG	donor_loss	0.9900
X:48008375:GGGCT:G	acceptor_gain	0.9900
X:48008530:TCATG:T	donor_gain	0.9900
X:48008533:TG:T	donor_gain	0.9900
X:48008534:GG:G	donor_gain	0.9900
X:48008535:G:GG	donor_gain	0.9900
X:48009362:TCA:T	acceptor_loss	0.9900
X:48009364:A:AG	acceptor_gain	0.9900
X:48009364:AGAC:A	acceptor_loss	0.9900
X:48009365:G:GA	acceptor_gain	0.9900
X:48009365:GAC:G	acceptor_gain	0.9900
X:48009365:GACCT:G	acceptor_gain	0.9900
X:48060542:CACC:C	acceptor_gain	0.9900
X:48060544:CC:C	acceptor_gain	0.9900
X:48060545:CC:C	acceptor_gain	0.9900

AlphaMissense

3558 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:48058786:A:C	F552L	0.995
X:48058786:A:T	F552L	0.995
X:48058788:A:G	F552L	0.995
X:48058954:G:C	F496L	0.995
X:48058954:G:T	F496L	0.995
X:48058956:A:G	F496L	0.995
X:48059038:A:C	F468L	0.994
X:48059038:A:T	F468L	0.994
X:48059040:A:G	F468L	0.994
X:48058870:G:C	F524L	0.993
X:48058870:G:T	F524L	0.993
X:48058872:A:G	F524L	0.993
X:48058769:A:G	L558P	0.991
X:48059122:G:C	F440L	0.991
X:48059122:G:T	F440L	0.991
X:48059124:A:G	F440L	0.991
X:48058757:T:G	Q562P	0.990
X:48058925:T:G	Q506P	0.990
X:48058853:A:G	L530P	0.989
X:48059021:A:G	L474P	0.989
X:48058937:A:G	L502P	0.988
X:48058915:A:C	H509Q	0.987
X:48058915:A:T	H509Q	0.987
X:48059290:G:C	F384L	0.987
X:48059290:G:T	F384L	0.987
X:48059292:A:G	F384L	0.987
X:48059374:G:C	F356L	0.987
X:48059374:G:T	F356L	0.987
X:48059376:A:G	F356L	0.987
X:48058702:G:C	F580L	0.986

dbSNP variants (sampled 300 via entrez): RS1000187500 (X:48070859 G>A,C), RS1000455425 (X:48062654 A>T), RS1000727379 (X:48070335 G>A,C,T), RS1001189150 (X:48072707 G>T), RS1001467389 (X:48064555 C>T), RS1001772490 (X:48064791 G>A,C), RS1002430636 (X:48066147 T>C), RS1002871999 (X:48066649 T>C), RS1003357672 (X:48059414 C>G), RS1003932265 (X:48062272 A>G), RS1004442525 (X:48069560 G>A), RS1004898191 (X:48063694 C>A), RS1004929222 (X:48064010 G>C,T), RS1005505000 (X:48071751 C>G), RS1005845700 (X:48071488 G>A,C)

Disease associations

OMIM: gene MIM:300819 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Valproic Acid	decreases expression	2
FR900359	increases phosphorylation	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
CGP 52608	affects binding, increases reaction	1
tanespimycin	increases expression, affects cotreatment	1
abrine	increases expression	1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide	increases expression	1
STA 9090	increases expression	1
VER 155008	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Silicon Dioxide	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists